Timothy C Thompson
Overview
Explore the profile of Timothy C Thompson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
3065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Han Y, Zhang M, Xu J, Li J, Xu Y, Thompson T, et al.
Am J Cancer Res
. 2021 Apr;
11(3):968-978.
PMID: 33791167
Most of screening-detected prostate cancer (PCa) are indolent and not lethal. Biomarkers that can predict aggressive diseases independently of clinical features are needed to improve risk stratification of localized PCa...
12.
Gregg J, Thompson T
Nat Rev Urol
. 2021 Feb;
18(3):170-184.
PMID: 33637962
Therapeutic gene manipulation has been at the forefront of popular scientific discussion and basic and clinical research for decades. Basic and clinical research applications of CRISPR-Cas9-based technologies and ongoing clinical...
13.
Ranasinghe W, Shapiro D, Hwang H, Wang X, Reichard C, Elsheshtawi M, et al.
Eur Urol
. 2020 Dec;
79(2):298-306.
PMID: 33279304
Background: Ductal prostate adenocarcinoma (DAC) is a rare, aggressive, histologic variant of prostate cancer that is treated with conventional therapies, similar to high-risk prostate adenocarcinoma (PAC). Objective: To assess the...
14.
Vykoukal J, Fahrmann J, Gregg J, Tang Z, Basourakos S, Irajizad E, et al.
Nat Commun
. 2020 Aug;
11(1):4279.
PMID: 32855410
Plasma and tumor caveolin-1 (Cav-1) are linked with disease progression in prostate cancer. Here we report that metabolomic profiling of longitudinal plasmas from a prospective cohort of 491 active surveillance...
15.
Vykoukal J, Fahrmann J, Thompson T
Cancer Metastasis Rev
. 2020 May;
39(2):341-342.
PMID: 32417992
No abstract available.
16.
Msaouel P, Malouf G, Su X, Yao H, Tripathi D, Soeung M, et al.
Cancer Cell
. 2020 May;
37(5):720-734.e13.
PMID: 32359397
Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young individuals of African descent and is resistant to all targeted agents used to treat other renal cell...
17.
Deng Y, Xie K, Logothetis C, Thompson T, Kim J, Huang M, et al.
Carcinogenesis
. 2020 Mar;
41(8):1057-1064.
PMID: 32215555
Background: Epithelial-mesenchymal transition (EMT) plays a pivotal role in the progression of prostate cancer (PCa). However, little is known about genetic variants in the EMT pathway as predictors of aggressiveness,...
18.
Xu J, Chang W, Tsai C, Bau D, Xu Y, Davis J, et al.
EBioMedicine
. 2020 Jan;
52:102616.
PMID: 31981976
Background: Telomeres play important roles in cancer initiation and progression. The aim of this study is to investigate whether leukocyte telomere length (LTL) is associated with aggressive prostate cancer (PCa)....
19.
Corn P, Heath E, Zurita A, Ramesh N, Xiao L, Sei E, et al.
Lancet Oncol
. 2019 Sep;
20(10):1432-1443.
PMID: 31515154
Background: Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the...
20.
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al.
Clin Cancer Res
. 2019 Aug;
25(22):6839-6851.
PMID: 31439587
Purpose: In this study, we addressed the underlying mechanisms for the association between enzalutamide (ENZ) treatment and neuroendocrine prostate cancer (NEPC), and the critical involvement of MYCN, and loss of...